Atrophic Alveolar Ridge
Conditions
Interventions
Homogeneous Circular Cortical-lamina Anchoring group:circular cortical-lamina anchoring technique was applied with homogeneous circular cortical lamina
Autologous Circular Cortical -lamina Anchoring group:circular cortical-lamina anchoring technique was applied with autologous circular cortical lamina
Sponsors
Stomatological Hospital, School of Stomatology, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Voluntarily sign informed consent; Mandibular dentition defect with at least one tooth position and does not require a second operative area during the surgical procedure ; According to Cawood and Howell classification, patients diagnosed with Class IV bone defect (i.e. knife-edge alveolar ridge with insufficient horizontal bone width and sufficient vertical bone height ) had a bone width < 4 mm at 1 mm below the alveolar ridge. Systemically healthy patients (American Society of Anesthesiologists - ASA Class I and II: mild complications other than surgical disease, functional compensation is sound); The patient was more than 18 years old at the time of the first operation and had good medical compliance. The periodontal status was in the periodontal maintenance period (plaque index < 20%, probing bleeding score < 10%); Implant surgery was chosen for treatment
Exclusion criteria
Exclusion criteria: Patients with contraindications for routine implant surgery or uncontrollable systemic diseases; 1) Severe systemic diseases: a. Hypertension, with systolic blood pressure (high pressure) > 150 mmHg or diastolic blood pressure (low pressure) > 90 mmHg. b. Uncontrolled diabetes: fasting blood sugar = 7.0 mmol/L or glycated hemoglobin (HbA1c > 7%). c. Heart disease (class 3-4 heart function), or symptoms such as orthopnea, lower limb edema. d. Cardiopulmonary disease, heart failure patients. e. Cerebrovascular and cardiovascular diseases (In the past six months, angina pectoris, myocardial infarction, cerebral infarction occurred. Recent episodes of angina pectoris are frequent). f. Third-degree or second-degree type II atrioventricular block, bifascicular block, Adams-Stokes syndrome. g. Heart valve disease. h. Acute hepatitis (which can cause severe liver damage). i. Severe asthma, severe pharyngitis, severe depression. j. Severe hyperthyroidism: pulse > 100 beats per minute, basal metabolic rate > 20%. k. Hematological diseases: hemophilia, leukemia, and other bleeding disorders, or coagulation disorders due to anticoagulant medication, INR > 3 or clinically significant abnormalities in coagulation panel. 2) Long-term use of the following medications: a. Intravenous and high-dose oral bisphosphonates for the prevention of bone metastasis and treatment of osteoporosis. b. Avascular necrosis of the joint due to the use of steroidal drugs (typical cases: SARS patients). c. Long-term treatment with adrenal corticosteroids. 3) Patients with AIDS, syphilis, and drug abusers. 4) Patients with other systemic diseases that make them unable to tolerate surgery. 5) Pathological changes in the alveolar bone. Acute or severe infection accompanied by a white blood cell count > 10×10^9/L. Maxillary sinus effusion greater than one-third. Abnormal occlusal relationships or bad occlusal habits around the edentulous area that may lead to traumatic resorption of bone around the implant and cause surgical failure; oral mucosal lesions; severe soft tissue lesions in the edentulous area; limited mouth opening; History of drug allergy: severe allergic reactions to anesthetics, anti-inflammatory and analgesics, and other medications used during and after surgery. Pregnant, menstruating, or lactating women. Uncontrolled periodontal disease or poor oral hygiene habits that cannot be improved (probing depth > 4mm, BOP > 10%). Need for a second surgical area for bone augmentation surgery. Heavy smokers (> 10 cigarettes per day). Patients with bone metabolic diseases: currently taking medications that may affect bone metabolism. History of malignant tumors, within 5 years of radiotherapy or chemotherapy for malignant tumors. The researcher considers other reasons not suitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alveolar ridge width; | — |
Secondary
| Measure | Time frame |
|---|---|
| Implant success rate;Operation duration;Postoperative adverse reactions and complications;marginal bone loss; | — |
Countries
China
Contacts
Public ContactGuo Zehong
Stomatological Hospital, School of Stomatology, Southern Medical University
Outcome results
None listed